Online inquiry

IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5576MR)

This product GTTS-WQ5576MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5576MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8166MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ5921MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ14040MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ4517MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ11144MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ14355MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ10362MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ14222MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-6107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW